The experimental models of parkinson's disease in animals

被引:0
|
作者
Grigoryan, G.A. [1 ]
Bazyan, A.S. [1 ]
机构
[1] Institute of Higher Nervous Activity and Neurophysiology, RAN, Moscow
来源
Uspekhi Fiziologicheskikh Nauk | 2007年 / 38卷 / 04期
关键词
Nigrostriatal dopaminergic system - Sporadic form - Toxic protein;
D O I
暂无
中图分类号
学科分类号
摘要
The current review describes the modern Parkinson's disease models in animals, their advantages, limitations and disadvantages. It was noted that the most widespread up-to-date models based on etiology of the Parkinson's disease. Although toxins mostly produce the Parkinson's disease, a study of involved genes allows investigating not only inherited but also sporadic (not inherited) forms of disease since the same genes are involved in both cases. Mutations of genes lead to formation of mutant toxic proteins, which produce a death of the specialized neurons of the nigrostriatal dopaminergic system and the development of Parkinson's disease. A significant place in the review takes a description of characteristics of the toxic models produced by 6-OHDA, MPTP and rotenone, their similarities and differences in pathogenetic mechanisms of the Parkinson's disease development. On the basis of the considered experimental models of Parkinson's disease a conclusion has been done that none of these models may in full and adequate scale imitate the entire clinical, pathophysiological, morphological, biochemical and other aspects of the Parkinson's disease development.
引用
收藏
页码:80 / 88
相关论文
共 50 条
  • [41] Models of Parkinson's disease in vitro
    Dilzoda, A.
    MOVEMENT DISORDERS, 2018, 33 : S391 - S391
  • [42] Animal Models of Parkinson's Disease
    Imai, Yuzuru
    Venderova, Katerina
    Park, David S.
    Cai, Huaibin
    Schmidt, Enrico
    PARKINSONS DISEASE, 2011, 2011
  • [43] Animal Models of Parkinson's Disease
    Halbach, O. von Bohlen Und
    NEURODEGENERATIVE DISEASES, 2005, 2 (06) : 313 - 320
  • [44] Animal models of Parkinson's disease
    Betarbet, R
    Sherer, TB
    Greenamyre, JT
    BIOESSAYS, 2002, 24 (04) : 308 - 318
  • [45] MPTP models of Parkinson's disease
    Fornai, F.
    Lenzi, P.
    Biagioni, F.
    Ruggieri, S.
    Paparelli, A.
    BEHAVIOURAL PHARMACOLOGY, 2006, 17 (5-6): : 541 - 541
  • [46] Primate models of Parkinson's disease
    Collier, TJ
    Steece-Collier, K
    Kordower, JH
    EXPERIMENTAL NEUROLOGY, 2003, 183 (02) : 258 - 262
  • [47] Drosophila Models of Parkinson's Disease
    Whitworth, Alexander J.
    ADVANCES IN GENETICS, VOL 73, 2011, 73 : 1 - 50
  • [48] Experimental therapeutics of Parkinson's disease
    Henderson, JM
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2003, 30 (11) : 841 - 844
  • [49] Downregulation of s-nitrosoglutathione reductase induces neuroprotection in experimental models of Parkinson's disease
    Rizza, S.
    Montagna, C.
    Cardaci, S.
    Di Giacomo, G.
    Ciriolo, M. R.
    Filomeni, G.
    FEBS JOURNAL, 2011, 278 : 273 - 274
  • [50] Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia
    Hallett, Penelope J.
    Brotchie, J. M.
    MOVEMENT DISORDERS, 2007, 22 (01) : 28 - 40